{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:27:32Z","timestamp":1793600852548,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.diabres.2026.113083","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:11:08Z","timestamp":1768407068000},"page":"113083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study"],"prefix":"10.1016","volume":"235","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1036-5390","authenticated-orcid":false,"given":"Alhena","family":"Younis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex E.","family":"Henney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Anson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-7353","authenticated-orcid":false,"given":"Sizheng S.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema H.","family":"Ibarburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayaz A","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Cuthbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.diabres.2026.113083_b0005","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Collaborators","year":"2022","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.diabres.2026.113083_b0010","unstructured":"Organisation, W.H. The top 10 causes of death. 2025; Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"10.1016\/j.diabres.2026.113083_b0015","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0140-6736(17)33185-9","article-title":"Global and regional economic costs of dementia: a systematic review","volume":"390","author":"Xu","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.diabres.2026.113083_b0020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2337\/dc15-1588","article-title":"Type 2 Diabetes as a risk factor for Dementia in Women Compared with men: a Pooled Analysis of 2.3 Million People Comprising more than 100,000 cases of Dementia","volume":"39","author":"Chatterjee","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2026.113083_b0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jalz.2015.12.003","article-title":"Why has therapy development for dementia failed in the last two decades?","volume":"12","author":"Gauthier","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"7","key":"10.1016\/j.diabres.2026.113083_b0030","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jgs.18405","article-title":"Is it time to repurpose geroprotective diabetes medications for prevention of dementia?","volume":"71","author":"He","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.diabres.2026.113083_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/diseases8020014","article-title":"SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?","volume":"8","author":"Saisho","year":"2020","journal-title":"Diseases"},{"issue":"10296","key":"10.1016\/j.diabres.2026.113083_b0040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.diabres.2026.113083_b0045","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113083_b0050","unstructured":"NICE, Type 2 diabetes in adults. 2023."},{"issue":"1","key":"10.1016\/j.diabres.2026.113083_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010065","article-title":"GLP1 Receptor Agonists-Effects beyond Obesity and Diabetes","volume":"13","author":"Wilbon","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.diabres.2026.113083_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1277113","article-title":"Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Cai","year":"2024","journal-title":"Front Public Health"},{"issue":"8","key":"10.1016\/j.diabres.2026.113083_b0065","doi-asserted-by":"crossref","first-page":"e2427258","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in individuals with Type 2 Diabetes","volume":"7","author":"Chuang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.diabres.2026.113083_b0070","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209805","article-title":"SGLT2 Inhibitor Use and risk of Dementia and Parkinson Disease among patients with Type 2 Diabetes","volume":"103","author":"Kim","year":"2024","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.diabres.2026.113083_b0075","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.diabres.2026.113083_b0080","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/ADR-230181","article-title":"Clinical evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: aSystematic Review","volume":"8","author":"Liang","year":"2024","journal-title":"J Alzheimers Dis Rep"},{"issue":"2","key":"10.1016\/j.diabres.2026.113083_b0085","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2026.113083_b0090","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"issue":"7","key":"10.1016\/j.diabres.2026.113083_b0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.21016","article-title":"Neurodegeneration and Stroke after Semaglutide and Tirzepatide in patients with Diabetes and Obesity","volume":"8","author":"Lin","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.diabres.2026.113083_b0100","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.diabres.2026.113083_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102689","article-title":"Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study","volume":"73","author":"Tang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabres.2026.113083_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113537","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: a Large-Scale Propensity-Matched cohort study","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.diabres.2026.113083_b0115","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","author":"Xie","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.diabres.2026.113083_b0120","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13195-024-01573-x","article-title":"Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","volume":"16","author":"Koychev","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.diabres.2026.113083_b0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.diabres.2026.113083_b0130","unstructured":"Nordisk, N. Novo Nordisk A\/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. 2025; Available from: https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916462."},{"key":"10.1016\/j.diabres.2026.113083_b0135","article-title":"Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial","author":"Edison","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2026.113083_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"issue":"19","key":"10.1016\/j.diabres.2026.113083_b0145","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial","volume":"110","author":"Krumholz","year":"2024","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.diabres.2026.113083_b0150","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ckj\/sfac274","article-title":"Tirzepatide and prevention of chronic kidney disease","volume":"16","author":"Bosch","year":"2023","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.diabres.2026.113083_b0155","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113083_b0160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","article-title":"A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease","volume":"812","author":"Yuan","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.diabres.2026.113083_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108042","article-title":"A GLP-1\/GIP\/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca(2+) homeostasis in 3xTg-AD mice","volume":"170","author":"Li","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.diabres.2026.113083_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.151016","article-title":"GLP-1 receptor signaling restores aquaporin 4 subcellular polarization in reactive astrocytes and promotes amyloid \u03b2 clearance in a mouse model of Alzheimer's disease","volume":"741","author":"Sasaki","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.diabres.2026.113083_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1146960","article-title":"Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats","volume":"14","author":"Guo","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2026.113083_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102019","article-title":"The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice","volume":"89","author":"Forny Germano","year":"2024","journal-title":"Mol Metab"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:38:57Z","timestamp":1793597937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"alternative-id":["S0168822726000021"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113083","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113083"}}